Castle Biosciences
CSTL
148 hedge funds and large institutions have $502M invested in Castle Biosciences in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 63 increasing their positions, 37 reducing their positions, and 18 closing their positions.
13,620% more call options, than puts
Call options by funds: $686K | Put options by funds: $5K
70% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less capital invested
Capital invested by funds: $514M → $502M (-$12.4M)
1.03% less ownership
Funds ownership: 84.15% → 83.12% (-1%)
3% less funds holding
Funds holding: 153 → 148 (-5)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Principal Financial Group
Des Moines,
Iowa
|
+$9.19M |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$4.12M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.91M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.8M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$7.99M |
| 2 |
RI
RTW Investments
New York
|
-$6.32M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$5.93M |
| 4 |
Goldman Sachs
New York
|
-$2.66M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$2.52M |
CSTL Hedge Fund Activity: Q1 2023 in Review
148 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q1 2023, worth a combined $502M — down 2.4% from $514M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CSTL and 15 opened new positions — a net loss of 3 holders — while 37 trimmed existing stakes and 63 added.
The largest buyer was Principal Financial Group, adding an estimated $9.19M. The largest seller was Portolan Capital Management, cutting an estimated $7.99M.
- 148 institutional investors held Castle Biosciences (CSTL) as of Q1 2023, down from 153 in Q4 2022.
- Funds reported $502M of Castle Biosciences stock for Q1 2023, down 2.4% quarter-over-quarter.
- 15 funds opened new Castle Biosciences positions in Q1 2023 and 18 closed out, a net change of -3 holders.
- The largest Castle Biosciences buyer in Q1 2023 was Principal Financial Group, an estimated $9.19M added.
- The largest Castle Biosciences seller in Q1 2023 was Portolan Capital Management, an estimated $7.99M sold.
Based on aggregated 13F filings for Q1 2023.